awmsg logo



bortezomib (Velcade®)


Reference No. 2357

Excluded date:
20/02/2015


Appraisal information

bortezomib (Velcade®) powder for solution for injection


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
   
   
Submission Type: Unspecified
Status: Excluded

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

Indication

In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

AWMSG advice

Product meets AWMSG exclusion criteria due to NICE appraisal